As reported on Becker’s Hospital Review, the U.S. Food and Drug Administration (FDA) has issued updated guidance targeting how telehealth companies promote compounded medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists. The agency emphasized that misleading marketing practices surrounding these products violate federal law and may undermine patient safety by distorting informed decision-making.
At the center of the update are five categories of promotional behavior the FDA considers inappropriate and still widespread. These include presenting a telehealth platform as though it manufactures or compounds medications itself, portraying compounded drugs as interchangeable with approved therapies, and suggesting that such products have undergone FDA approval or safety evaluation. The agency also cautioned against claims that compounded formulations perform equivalently to branded drugs, as well as references to sourcing from so-called “FDA-approved” or “FDA-licensed” facilities—designations the agency noted do not exist in this context.
The clarification is part of a broader escalation in regulatory oversight. Since late 2025, the FDA has intensified scrutiny of telehealth-driven pharmaceutical marketing, particularly in response to the rapid rise of compounded GLP-1 drugs. In March 2026, the agency issued 30 warning letters to companies for similar promotional violations, marking the second major round of enforcement actions in this space. This follows a wave of notices sent the previous fall that exceeded the total number of such actions taken over the prior decade.
Additional steps have reinforced the agency’s position. In April 2026, the FDA signaled plans to restrict compounding of GLP-1 therapies once supply shortages of branded products are resolved. Around the same time, regulators cited a compounding facility for sterility issues related to semaglutide and tirzepatide production, raising further concerns about manufacturing practices.
The growing attention reflects the significant role compounded GLP-1 drugs have played in the U.S. market. During 2024, these alternatives represented as much as 30% of total utilization, driven largely by ongoing shortages of brand-name medications from major pharmaceutical manufacturers and aggressive direct-to-consumer marketing by telehealth providers.
Although the latest update does not introduce new enforcement actions, the FDA reiterated its commitment to ongoing surveillance of promotional materials and indicated that further regulatory steps may follow. The agency’s overarching goal remains ensuring that patients receive accurate, transparent information when considering treatment options, particularly in rapidly evolving areas such as weight management and metabolic disease therapeutics.
